AstraZeneca reveals early data for oral PCSK9, touts PK edge over Merck’s drug
AstraZeneca has unveiled the early efficacy profile of its oral PCSK9 inhibitor in patients with high levels of “bad” cholesterol.
One arm of the Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
